US Patent 8,785,427: Cortexolone-17α-Propionate Form III Claims, Scope and Patent Landscape
US Patent 8,785,427 protects a specific manufacturing route, crystalline Form III of cortexolone-17α-propionate, and pharmaceutical compositions containing that polymorph. It does not claim clascoterone in every chemical form, every manufacturing process, or every topical formulation. The patent is directed to the active pharmaceutical ingredient now marketed as clascoterone, including the polymorphic form used in Winlevi.
The strongest commercial coverage is the combination of claims 20-23, which define Form III by diffraction, thermal, and infrared signatures, and claims 24-29, which cover compositions containing that form. Claims 1-19 create process barriers around enzymatic preparation and crystallization.
What drug and technology does US 8,785,427 cover?
US 8,785,427 covers cortexolone-17α-propionate, also known as clascoterone, in crystalline Form III. Clascoterone is a topical androgen-receptor inhibitor approved by the FDA under the brand name Winlevi for acne vulgaris in patients 12 years of age and older.[2]
The patent has three technical layers:
| Claim group |
Subject matter |
Commercial significance |
| Claims 1-19 |
Enzymatic preparation and crystallization of Form III |
Can block a competing API manufacturing route |
| Claims 20-23 |
Crystalline Form III defined by DRX, DSC and IR data |
Can cover the isolated API regardless of manufacturing route |
| Claims 24-29 |
Pharmaceutical compositions containing Form III |
Can reach drug products using the polymorph |
“DRX” refers to X-ray diffraction, generally powder X-ray diffraction. DSC refers to differential scanning calorimetry. IR refers to infrared spectroscopy. The patent uses these analytical fingerprints to distinguish Form III from other cortexolone-17α-propionate polymorphs or solid-state forms.[1]
What are the independent claims in US 8,785,427?
The material independent claims are claims 1, 20 and 24.
Claim 1: enzymatic manufacturing process
Claim 1 requires all of the following:
- A reaction involving a compound of formula II.
- An alcohol of formula III, R'OH.
- An organic solvent.
- A lipase from Candida.
- R equal to an ethyl group in compound II.
- Formation of cortexolone-17α-propionate.
- Crystallization from one of three solvent systems:
- dichloromethane/n-hexane;
- acetone/n-hexane; or
- ethanol/water.
- Recovery of crystalline Form III.
The claim is narrower than a general process claim for producing clascoterone. A process that uses a non-Candida enzyme, chemical hydrolysis or esterification, a different solvent system, or a different crystallization pathway may avoid literal infringement of claim 1, subject to equivalents analysis.
The claim also requires the final material to be Form III. A competing process producing clascoterone in an amorphous state or a different polymorph would not literally satisfy that limitation.
Claim 20: crystalline Form III
Claim 20 covers crystalline Form III characterized by the claimed combinations of:
- DRX spectrum shown in Figure 7, 10 or 13;
- DSC spectrum shown in Figure 8, 11 or 14; and
- IR spectrum shown in Figure 9, 12 or 15.
Claims 21-23 narrow the product claim to each of the three analytical combinations.
This is the principal product claim. It is not limited to material made by the Candida-lipase process in claim 1. A generic or contract manufacturer could infringe claims 20-23 by producing Form III through a different route.
The practical enforcement question is whether the accused batch meets the claimed analytical profile. A product analysis would ordinarily compare powder X-ray diffraction peaks, thermal transition behavior and IR spectra against the patent figures and specification. The claim language does not provide numerical peak lists in the supplied claims, which may create claim-construction and proof issues if the figures do not define sufficiently objective boundaries.
Claim 24: pharmaceutical composition
Claim 24 covers a pharmaceutical composition containing crystalline Form III and at least one physiologically acceptable excipient.
Claims 25-29 extend the coverage across dosage forms, including:
- tablets;
- capsules;
- powders;
- pellets;
- suspensions;
- emulsions;
- solutions;
- creams;
- gels;
- ointments;
- lotions; and
- pastes.
The claims are broad as to dosage form. Claim 29 specifically covers an ointment containing Form III. A topical generic using the same polymorph in a cream, gel or ointment could face composition-claim exposure even if it avoids the patented manufacturing process.
How broad are the process claims?
The dependent claims add operating ranges and materials that narrow claim 1.
| Claims |
Limitation |
| 2 |
R' is an aliphatic chain containing 1-8 carbon atoms |
| 3-4 |
Aprotic solvent, including toluene, acetonitrile, THF, dichloromethane or chloroform |
| 5-6 |
Formula II concentration of about 0.01-0.15 M, preferably about 0.025 M |
| 7 |
Methanol, ethanol, butanol, octanol or combinations |
| 8-9 |
Alcohol at about 0.5-50 molar equivalents, specifically about 5 equivalents |
| 10 |
Candida cylindracea or Candida antarctica type B |
| 11-12 |
Defined enzyme activity ranges |
| 13 |
Reaction temperature of about 10-48°C |
| 14-19 |
Specific crystallization solvent systems, ratios and analytical profiles |
Claim 1 already includes the three crystallization solvent families. Claims 14-19 provide narrower embodiments with specific solvent ratios:
| Claim |
Crystallization system |
Ratio |
| 14-15 |
Dichloromethane/n-hexane |
About 1:30 |
| 16-17 |
Acetone/n-hexane |
About 1:8 |
| 18-19 |
Ethanol/water |
About 1:2 |
The process estate is therefore layered. A competitor may avoid the narrower dependent claims while remaining exposed to claim 1, but only if every claim 1 limitation is present.
What formulation protection does US 8,785,427 provide?
The formulation claims are polymorph-dependent, not formulation-platform claims. They require crystalline Form III as the active solid material.
The patent does not, based on the supplied claims, require:
- a particular active concentration;
- a specific vehicle;
- a particular dermatological indication;
- a specific particle-size distribution;
- a defined penetration enhancer;
- a particular preservative system; or
- a specified release profile.
This gives claims 24-29 broad coverage against dosage forms containing Form III. It also limits their reach. A composition using a different clascoterone polymorph, amorphous clascoterone or a solution in which the claimed crystalline form is absent could present a noninfringement position, depending on product composition and claim construction.
The claims do not independently cover the clinical use of clascoterone for acne, androgenetic alopecia or other androgen-mediated conditions. Those rights must be assessed in separate method-of-use patents.
When does US 8,785,427 lose exclusivity?
The patent issued on July 22, 2014.[1] Public patent and Orange Book data identify a 2029 patent-term endpoint for the patent family, subject to the controlling patent-term calculation and any applicable adjustment.[3]
| Event |
Date or status |
| US patent issued |
July 22, 2014 |
| FDA approval of Winlevi |
August 26, 2020 |
| Regulatory exclusivity |
Five-year NCE period associated with the original approval |
| Patent endpoint |
2029, reported in FDA patent-listing data |
| Earliest ordinary generic approval pathway |
After applicable regulatory exclusivity and subject to patent litigation or settlement |
The FDA approved Winlevi on August 26, 2020. The five-year new chemical entity exclusivity period therefore ran to approximately August 26, 2025, absent a different FDA calculation or pediatric extension.[2] Patent protection extends beyond that regulatory period.
Regulatory exclusivity and patent protection are separate. Expiration of NCE exclusivity permits certain abbreviated applications to proceed, but does not remove the need to address listed patents.
What is the Orange Book status of US 8,785,427?
US 8,785,427 has been associated with Winlevi and clascoterone topical products in FDA patent-listing information.[3] Its significance is primarily pharmaceutical and solid-state:
- it can be listed against the approved drug;
- it can support a Paragraph IV notice if an ANDA applicant asserts that the patent is invalid, unenforceable or not infringed;
- it can delay approval through the statutory 30-month stay if the NDA holder or patent owner brings timely infringement litigation.
The patent is not a conventional method-of-use patent. Its Orange Book relevance comes from the crystalline active ingredient and compositions containing that ingredient.
The exact listing status should be evaluated against the current FDA Orange Book entry, including whether the patent is listed for the approved product, whether any delisting or expiration update has occurred, and whether additional patents are listed for the same NDA.[3]
What Paragraph IV challenges and generic-entry risks exist?
A generic applicant seeking approval for clascoterone topical product could pursue several strategies.
Strategy 1: use Form III and challenge the patent
An ANDA applicant could use the same or an equivalent Form III and file a Paragraph IV certification against US 8,785,427. The applicant would likely challenge:
- anticipation or obviousness of Form III;
- enablement and written description;
- indefiniteness of claims defined by figures;
- infringement based on analytical differences;
- validity of the process claims;
- enforceability, if supported by the prosecution record.
This route creates direct litigation risk because the product claims do not depend on use of the patented Candida process.
Strategy 2: use a different polymorph
A different crystalline form, amorphous form or solution could reduce exposure to claims 20-29. This approach would require control of:
- solid-state conversion;
- polymorphic stability;
- particle morphology;
- dissolution;
- topical uniformity;
- bioavailability and local skin delivery; and
- regulatory comparability.
A different polymorph may avoid this patent but encounter separate patents covering another form, a formulation, a manufacturing process or a method of treatment.
Strategy 3: design around the process claims
A manufacturer could use a non-Candida enzyme, a chemical route, a different precursor, a different solvent or a different crystallization system. This may avoid claims 1-19 while still requiring a non-infringing final solid form.
Strategy 4: 505(b)(2) or alternative regulatory route
A 505(b)(2) applicant could propose a modified topical formulation or dosage form. That pathway does not eliminate patent risk. The applicant would still need to address listed patents and any relevant method-of-use claims.
No public information supplied with the claim text establishes a filed ANDA, Paragraph IV notice, district-court complaint or settlement agreement specifically directed to US 8,785,427. A definitive litigation conclusion cannot be made from the claim text alone.
Which companies control the commercial patent position?
Winlevi was developed by Cassiopea, a Cosmo Pharmaceuticals company, and approved by the FDA in 2020.[2] Commercial rights have involved Cosmo Pharmaceuticals and its U.S. commercialization arrangements. The patent itself is associated with the Cosmo/Cassiopea clascoterone development program.[1,2]
The competitive landscape includes:
| Competitor category |
Risk to US 8,785,427 |
| Generic topical clascoterone |
High if it uses Form III |
| Alternative-polymorph manufacturer |
Lower direct risk, but exposed to other patents |
| 505(b)(2) topical product |
Moderate to high, depending on active form and listed patents |
| Compounded clascoterone |
Commercially relevant but not an ANDA generic; patent and regulatory exposure differs |
| New androgen-receptor topical therapy |
Does not directly infringe unless it uses clascoterone or the claimed form |
How strong is the patent estate?
US 8,785,427 has meaningful but defined strength.
Strengths
- Claims 20-23 are product claims rather than process-only claims.
- The product claims can reach Form III made by a noninfringing process.
- Claims 24-29 extend protection into topical and non-topical dosage forms.
- The three crystallization routes provide process redundancy.
- The patent covers the polymorph associated with the commercial API program.
Weaknesses and design-around opportunities
- The patent does not claim all clascoterone.
- A verified different polymorph may avoid the product and composition claims.
- Process claims require a specific Candida-lipase pathway and crystallization outcome.
- Figure-based analytical limitations may produce disputes over claim boundaries.
- Separate later patents may provide the more important barriers for commercial formulation, treatment methods or manufacturing.
Patent strength should therefore be assessed as part of the complete clascoterone estate, not in isolation.
What patent litigation affects clascoterone generic entry?
The supplied record identifies no specific litigation, Paragraph IV settlement or authorized-generic agreement concerning US 8,785,427. The principal litigation risk would arise when an ANDA applicant certifies Paragraph IV against the patent and the NDA holder or patent owner files within the statutory period.
Potential litigation issues include:
- Whether the proposed generic contains Form III.
- Whether the generic's DRX, DSC and IR profiles fall within claims 20-23.
- Whether the generic composition contains the claimed crystalline material.
- Whether the process used by the generic satisfies claim 1.
- Whether the patent is valid over prior polymorph and process disclosures.
- Whether the patent term or Orange Book listing supports a statutory stay.
A settlement could include a delayed generic launch, license, authorized generic supply arrangement or different-polymorph launch. No settlement terms are established by the supplied information.
Key Takeaways
- US 8,785,427 covers clascoterone crystalline Form III, not clascoterone in every form.
- Claims 20-23 are the central product claims and do not require use of the patented manufacturing process.
- Claims 1-19 cover Candida-lipase preparation followed by crystallization in specified solvent systems.
- Claims 24-29 cover pharmaceutical compositions containing Form III, including creams, gels and ointments.
- The patent was issued on July 22, 2014, and its reported patent-term endpoint is in 2029.
- FDA approval of Winlevi occurred on August 26, 2020, with five-year NCE exclusivity running approximately to August 26, 2025.
- The most credible generic design-around is a demonstrably different polymorph or non-crystalline formulation, subject to other patents.
- The patent does not itself establish protection for acne treatment methods, specific topical excipients or every clascoterone formulation.
- No specific Paragraph IV litigation or settlement is established by the supplied claim record.
FAQs
Does US 8,785,427 cover the active ingredient clascoterone broadly?
No. It covers a defined crystalline form of clascoterone and compositions containing that form. Other polymorphs, amorphous material and certain solutions may fall outside the literal claims.
Can a generic avoid US 8,785,427 by changing the manufacturing process?
Changing the process may avoid claims 1-19, but it will not avoid claims 20-29 if the resulting product contains crystalline Form III.
Does the patent cover Winlevi's acne indication?
The supplied claims do not recite acne treatment or another method of use. They cover the active polymorph, its preparation and compositions containing it.
Are crystalline Form III and amorphous clascoterone interchangeable for patent purposes?
No. Solid-state identity is central to the patent. An amorphous product may avoid Form III claims, but it must be evaluated against other patent claims and regulatory requirements.
What is the principal patent risk for a clascoterone topical generic?
The principal risk is product and composition infringement if the generic uses crystalline Form III. A non-Candida manufacturing process alone may not provide a sufficient design-around.
References
- United States Patent and Trademark Office. (2014). US Patent No. 8,785,427, Cortexolone 17α-propionate crystalline form III, process for its preparation and pharmaceutical compositions thereof.
- U.S. Food and Drug Administration. (2020, August 26). FDA approves new treatment for acne.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.